Ocular Oncology Clinical Trials
To learn more about clinical trials on treatments for eye disease please call or email the contact for the specific study below.
For a longer list of studies needing volunteers throughout the U-M Health System, please go to UMClinicalStudies.
On this page:
Title: VISmodegib for ORBital and periocular basal cell carcinoma (VISORB)
IRB Number: HUM00082579
Basal cell carcinoma (BCCA) is the most common human cancer, affecting approximately 750,000 Americans per year. BCCAs are generally treated by local excision, which in many cases is associated with scarring and potential disfigurement. Vismodegib is a medical treatment for BCCA, taken orally, and has been recently approved by the Food and Drug Administration (FDA). The purpose of this study is to follow the treatment course for orbital BCCA with Vismodegib and record medical information in order to determine whether treatment with Vismodegib improves the chance of maintaining functional vision and/or functional tear drainage system.
- 18 years of age or older
- Ability or willingness to swallow capsules
- Ability or willingness to comply with study procedures and protocol
- No pregnant, lactating or breast feeding women
- No women of childbearing potential.
- Sonal Trivedi, (734) 615-58560 firstname.lastname@example.org
- Principal Investigator: Alon Kahana, M.D., Ph.D.
There are currently no studies in this section.